Appropriate and inappropriate use of dronedarone in 2013

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Opinion statement: Dronedarone is a multichannel blocking antiarrhythmic agent that has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in several multi-center trials. In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. Dronedarone increased mortality and cardiovascular hospitalizations in a different patient group with permanent AF/AFl. Although organic toxicity from the drug is very rare, post-marketing data has reported rare hepatic toxicity associated with dronedarone use. Current guidelines position dronedarone as a front-line antiarrhythmic in many patients with AF/Fl. However, dronedarone should not be used in patients with advanced heart failure or in permanent AF. Clinical trial results have helped us define appropriate and inappropriate candidates for dronedarone.

Original languageEnglish (US)
Pages (from-to)467-475
Number of pages9
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume15
Issue number4
DOIs
StatePublished - Aug 1 2013

Fingerprint

Atrial Fibrillation
Atrial Flutter
Hospitalization
Heart Failure
Mortality
dronedarone
Marketing
Drug-Related Side Effects and Adverse Reactions
Clinical Trials
Guidelines
Recurrence
Liver
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{72bfea6a56d7404b8ec2b0e75c9a17ec,
title = "Appropriate and inappropriate use of dronedarone in 2013",
abstract = "Opinion statement: Dronedarone is a multichannel blocking antiarrhythmic agent that has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in several multi-center trials. In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. Dronedarone increased mortality and cardiovascular hospitalizations in a different patient group with permanent AF/AFl. Although organic toxicity from the drug is very rare, post-marketing data has reported rare hepatic toxicity associated with dronedarone use. Current guidelines position dronedarone as a front-line antiarrhythmic in many patients with AF/Fl. However, dronedarone should not be used in patients with advanced heart failure or in permanent AF. Clinical trial results have helped us define appropriate and inappropriate candidates for dronedarone.",
author = "Naccarelli, {Gerald V.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/s11936-013-0246-5",
language = "English (US)",
volume = "15",
pages = "467--475",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "4",

}

Appropriate and inappropriate use of dronedarone in 2013. / Naccarelli, Gerald V.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 15, No. 4, 01.08.2013, p. 467-475.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Appropriate and inappropriate use of dronedarone in 2013

AU - Naccarelli, Gerald V.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Opinion statement: Dronedarone is a multichannel blocking antiarrhythmic agent that has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in several multi-center trials. In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. Dronedarone increased mortality and cardiovascular hospitalizations in a different patient group with permanent AF/AFl. Although organic toxicity from the drug is very rare, post-marketing data has reported rare hepatic toxicity associated with dronedarone use. Current guidelines position dronedarone as a front-line antiarrhythmic in many patients with AF/Fl. However, dronedarone should not be used in patients with advanced heart failure or in permanent AF. Clinical trial results have helped us define appropriate and inappropriate candidates for dronedarone.

AB - Opinion statement: Dronedarone is a multichannel blocking antiarrhythmic agent that has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in several multi-center trials. In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. Dronedarone increased mortality and cardiovascular hospitalizations in a different patient group with permanent AF/AFl. Although organic toxicity from the drug is very rare, post-marketing data has reported rare hepatic toxicity associated with dronedarone use. Current guidelines position dronedarone as a front-line antiarrhythmic in many patients with AF/Fl. However, dronedarone should not be used in patients with advanced heart failure or in permanent AF. Clinical trial results have helped us define appropriate and inappropriate candidates for dronedarone.

UR - http://www.scopus.com/inward/record.url?scp=84881061014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881061014&partnerID=8YFLogxK

U2 - 10.1007/s11936-013-0246-5

DO - 10.1007/s11936-013-0246-5

M3 - Article

C2 - 23595414

AN - SCOPUS:84881061014

VL - 15

SP - 467

EP - 475

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 4

ER -